AstraZeneca PLC (AZN)

55.53 -1.05 (-1.86%) At close: 04:00PM EST

AstraZeneca PLC

1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
44 20 3749 5000
http://www.astrazeneca.com

Sector(s): Healthcare
Industry: Drug Manufacturers—General
Full-time employees: 76,100

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Pascal Soriot D.V.M., M.B.A.	CEO & Exec. Director	5.85M	N/A	1959
Mr. Marc Dunoyer	Chief Exec. Officer of Alexion	3.27M	N/A	1952
Dr. Aradhana Sarin M.D.	CFO & Exec. Director	N/A	N/A	1975
Ms. Pam P. Cheng	EVP of Operations & Information Technology and Member of External Sustainability Advisory Board	N/A	N/A	1971
Mr. Thomas Kudsk Larsen	Head of Investor Relations	N/A	N/A	1974
Mr. Jeffrey Pott	EVP of HR, Chief HR Officer, Gen. Counsel & Member of External Sustainability Advisory Board	N/A	N/A	N/A
Ms. Katarina Ageborg	EVP of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory Board	N/A	N/A	N/A
Dr. Menelas Pangalos Ph.D.	EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board	N/A	N/A	N/A
Dr. Ruud Dobber Ph.D.	Exec. Vice-Pres of BioPharmaceuticals Bus. Unit	N/A	N/A	N/A
Dr. Susan Mary Galbraith M.D., Ph.D.	Exec. VP of Oncology R&D	N/A	N/A	1966

Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Corporate governance

AstraZeneca PLC’s ISS governance QualityScore as of 26 September 2021 is 7. The pillar scores are Audit: 1; Board: 9; Shareholder rights: 1; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.